The companies will offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.
SeouLin Bioscience will distribute the company's cell line products in the Republic of Korea, and provide first-level technical support for local customers.
The deal was completed on May 1, following the expiration of a tender offer in which Cellular Dynamics' shareholders tendered 90 percent of the company's common stock.
NEW YORK (GenomeWeb) – Cellular Dynamics International today announced a $1.2 million contract from the National Eye Institute to manufacture stem cells for use in the development of a new potential treatment for dry age-related macular degeneration.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
